GIANT BioSystems, founded by a team of elite scientists from leading institutions such as Cornell, Caltech, Harvard, UCLA, and MIT (Dr. Ehsan Shirzaei Sani, CEO/Co-Founder; Dr. Morteza Azizi, CTO/Co-Founder; Canran Wang, COO/Co-Founder; and Samuel Solomon, CSO/Director of AI), is pioneering an AI/ML-assisted microfluidics-based platform for high-throughput antimicrobial susceptibility testing (AST) and drug/antibiotic discovery. GIANT’s patented microfluidics chip facilitates the simultaneous screening of over 50 antibiotics in just 3-5 hours with exceptional precision. The GIANT platform is cost-effective, compact, highly precise, and user-friendly, requiring no complex training.
